Snyder Mark Drugs Roselle, Inc. d.b.a. Mark Drugs Pharmacy

CLOSEOUT LETTER Snyder Mark Drugs Roselle, Inc. d.b.a. Mark Drugs Pharmacy MARCS-CMS 547409 — February 04, 2021 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: UPS Next Day Product: Drugs Recipient: Recipient Name Mark H. Mandel, PharmD Recipient Title Owner and Pharmacist-in-Charge Snyder Mark Drugs Roselle, Inc. d.b.a. Mark Drugs Pharmacy 384 E. Irving Park Road Roselle , IL 60172-2007 United States Issuing Office: Detroit District Office United States (313) 393-8100 Dear Dr. Mandel: The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (Case # 547409) dated February 27, 2018. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter. You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ Nicholas F. Lyons Director of Compliance Division of Pharmaceutical Quality Operations III Content current as of: 02/12/2021 Regulated Product(s) Drugs